Literature DB >> 9827969

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation.

E Vance1, S George, E C Guinan, C Wheeler, J H Antin, D M Ambrosino, D C Molrine.   

Abstract

Antibody concentrations to vaccine-preventable diseases decline following BMT and an optimal schedule for vaccination after transplant has not been established. We examined antibody responses to tetanus toxoid (TT) and Haemophilus influenzae type b-conjugate (HIB) vaccines of BMT patients immunized at 6, 12 and 24 months (6 month group, n = 21) and compared them to those previously reported for patients immunized at 3, 6, 12 and 24 months (3 month group, n = 74) or at 12 and 24 months (12 month group, n = 17) following transplantation. Geometric mean total anti-HIB and IgG anti-TT concentrations were significantly higher after the 12 month dose in the 3 and 6 month immunization groups compared to the group who received their first dose at 12 months. Although HIB antibody concentrations were higher in the 3 month and 6 month groups 12 to 24 months after BMT, the proportion of patients with protective levels was not significantly different from the proportion protected in the 12 month group. Following the 24 month immunizations, geometric mean antibody concentrations to HIB and TT were similar for all three immunization groups. The proportion of patients in each group with protective levels of HIB antibody after the 24 month dose was > or = 80%. A two dose schedule of HIB and TT vaccines at 12 and 24 months after BMT should afford protection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827969     DOI: 10.1038/sj.bmt.1701424

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Immunization for bone marrow transplant recipients.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2002-11

Review 2.  Immunization of children with secondary immunodeficiency.

Authors:  Susanna Esposito; Elisabetta Prada; Mara Lelii; Luca Castellazzi
Journal:  Hum Vaccin Immunother       Date:  2015-07-15       Impact factor: 3.452

3.  Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

Authors:  A Ambati; L S V Boas; P Ljungman; L Testa; J F de Oliveira; M Aoun; V Colturato; M Maeurer; C M Machado
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

4.  Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.

Authors:  Avinash K Shetty; Mary A Winter
Journal:  Ochsner J       Date:  2012

5.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

6.  Species-specific and cross-reactive IgG1 antibody binding to viral capsid protein 1 (VP1) antigens of human rhinovirus species A, B and C.

Authors:  Jua Iwasaki; Wendy-Anne Smith; Shane R Stone; Wayne R Thomas; Belinda J Hales
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

7.  Immune responses to inhalant allergens.

Authors:  Wayne R Thomas; Belinda J Hales
Journal:  World Allergy Organ J       Date:  2008-06       Impact factor: 4.084

8.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

9. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.